Pedro L. Moro

Pedro L. Moro

Auto-generated profile, based on publicly available information

Pedro L. Moro

Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Vaccine
Verified
Journal Article
Closed access
DGDiane Gubernot
Diane Gubernot
AJAmelia Jazwa
Amelia Jazwa
MNManette Niu
Manette Niu
JBJane Baumblatt
Jane Baumblatt
JGJulianne Gee
Julianne Gee
SBSarah Bennett
Sarah Bennett

4 May 2005 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
PMPedro L. Moro
Pedro L. Moro
HGHector H. Garcia
Hector H. Garcia
AGArmando E. Gonzales
Armando E. Gonzales
JBJuan J. Bonilla
Juan J. Bonilla
MVManuela Verastegui
Manuela Verastegui
RGRobert H. GilmanMD
Robert H. GilmanMD

1 October 2007 in American Journal of Infection Control
Verified
Journal Article
Closed access
PMPedro L. Moro
Pedro L. Moro
AMArelis Moore
Arelis Moore
PBPatricia Balcacer
Patricia Balcacer
AMAlex Montero
Alex Montero
DDDelissa Diaz
Delissa Diaz
BWBruce G. Weniger
Bruce G. Weniger

21 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PMPedro L Moro
Pedro L Moro
JLJessica Leung
Jessica Leung
PMPaige Marquez
Paige Marquez
YKYeowon Kim
Yeowon Kim
SWShaokui Wei
Shaokui Wei
MMMona Marin
Mona Marin
Background: . The Vaccine Adverse Event Reporting System (VAERS) is the United States national passive vaccine safety surveillance system. We updated the data on the safety of single-antigen varicella vaccine (VAR) and assessed the safety of combination measles, mumps, rubella, and varicella vaccine (MMRV) licensed in the United States using VAERS data.Methods: US VAERS reports received after administration of VAR and MMRV during 2006–2020 were identified. Reports were analyzed by vaccine type, age, seriousness, most common adverse events (AEs), and concomitant vaccines. We reviewed medical records of selected reports of AEs of special interest and conducted empirical Bayesian data mining to identify disproportionally reported AEs.Results: During 2006–2020, approximately 132.8 million VAR doses were distributed; 40 684 reports were received in VAERS (30.6/100 000 doses distributed), with 4.1% classified as serious (1.3/100 000 doses distributed). Approximately 35.5 million MMRV doses were distributed; 13 325 reports were received (37.6/100 000 doses distributed) with 3.3% classified as serious (1.3/100 000 doses distributed). The most common adverse health events after both VAR and MMRV were injection site reactions (31% and 27%), rash (28% and 20%), and fever (12% and 14%), respectively. Vaccination errors accounted for 23% of reports after VAR administration and 41% after MMRV administration, but ≥95% of them did not describe an adverse health event. AEs associated with evidence of vaccine strain varicella-zoster virus (vVZV) infection included meningitis, encephalitis, herpes zoster, and 6 deaths (all in immunocompromised persons with contraindications for vaccination). No new or unexpected AE was disproportionally reported.Conclusions: No new or unexpected safety findings were detected for VAR and MMRV given as recommended, reinforcing the favorable safety profiles of these vaccines. Providers should obtain specimens for viral testing and strain-typing for serious AEs if they consider vVZV as the possible causative agent.

3 October 2019 in Expert Review of Vaccines
Verified
Journal Article
Closed access
PMPedro L. Moro
Pedro L. Moro
PHPenina Haber
Penina Haber
MMMichael M. McNeil
Michael M. McNeil
Introduction: Vaccination is one of the most successful and cost-effective public health interventions. Although vaccines undergo extensive safety and efficacy evaluations prior to licensure, vaccine safety assessment post-licensure is essential for detecting rare and longer-term adverse events (AEs) and maintaining public confidence in vaccines and recommended immunization programs. Despite the proven effect of vaccines to save lives and prevent disease and overwhelming evidence of vaccines’ safety and societal benefit, like any drug, no vaccine can be considered as completely safe and completely effective. New vaccines continue to be introduced and require rapid safety assessment post-licensure through pharmacovigilance reports as well as epidemiologic studies to investigate any potential safety signals. Areas covered: We discuss selected challenges for conducting pharmacovigilance and epidemiologic studies of AEs after vaccination in the United States using the post-licensure safety surveillance infrastructure of the Centers for Disease Control and Prevention (CDC). Expert opinion: The availability of specific post-licensure surveillance systems to monitor and study AEs after vaccination such as the Vaccine Adverse Event Reporting System, the Vaccine Safety Datalink, and the Clinical Immunization Safety Assessment Project, each with its unique set of strengths and limitations, provide a harmonized and supportive approach to meet several of these barriers.

1 January 2008 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PMPedro L. Moro
Pedro L. Moro
CCCarlos A. Cavero
Carlos A. Cavero
MTMoises Tambini
Moises Tambini
YBYuri Briceño
Yuri Briceño
RJRosario Jiménez
Rosario Jiménez
LCLilia Cabrera
Lilia Cabrera
We conducted a questionnaire-based case-control study to identify risk factors for cystic echinococcosis (CE) in Lima, Peru during July-December 2005. Data were obtained from 32 cases and 64 controls. Multivariate conditional logistic regression showed that having owned > or =10 dogs [adjusted odds ratio (AOR) 8.7, 95% CI 1.3-57.5) and raising sheep (AOR 5.9, 95% CI 1.2-28.1) were independently associated with CE. The belief that CE could be transmitted by food (AOR 0.1, 95% CI 0.01-0.7) and breeding goats (AOR 0.02, 95% CI 0.001-0.6) were protective factors against CE transmission. Our results suggest that preventive measures to decrease the transmission of echinococcosis to humans in Peru should include limiting the number of dogs owned and encouraging owners to restrict dogs' access to food and water used for human consumption.